- Net loss widened to $20.4 million ($0.79 per share) vs. $4.6 million in Q3 2025.
- Dilution increased significantly with weighted-average shares up to 25.8M from 1.3M.
- Cash, cash equivalents and marketable securities stood at $174.8 million as of September 30, 2026.
Signal #114383 · SEC 8-K
$FTH SEC Filing Alert & Real-Time AI Stock Impact Analysis
Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).
FAQ: $FTH filing catalyst
Why did $FTH trigger an AI stock catalyst alert?
$FTH triggered a Stock Catalyst AI alert on 2026-11-03 00:00:00 UTC for a SEC 8-K filing (AI Score: -1.5/10). Headline: Faeth Therapeutics Reports Q3 Net Loss of $20.4M as Operating Expenses Surge. Key points: - Net loss widened to $20.4 million ($0.79 per share) vs. $4.6 million in Q3 2025. - Dilution increased significantly with weighted-average shares up to 25.8M from 1.3M. - Cash, cash equivalents and marketable securities stood at $174.8 million as of September 30, 2026.
How did $FTH stock react after the SEC filing?
After the SEC 8-K for $FTH, observed market reaction: T0 price $19.23. Past moves do not guarantee future results.
Where can I get real-time $FTH SEC filing alerts?
Stock Catalyst AI pushes real-time SEC 8-K alerts for $FTH via Telegram and the VIP Web Terminal from €10/month.